Medication vs. Therapy for High-Functioning Anxiety: A Trauma Therapist’s Clinical Guide
This isn’t an anti-medication post. It’s a precision guide for driven women with high-functioning anxiety who want to understand what SSRIs and therapy actually do at the neurobiological level, when each is appropriate, and how to sequence them intelligently. Written by a trauma therapist who treats the anxiety behind the accomplishment, not just the accomplishment that hides the anxiety.
- The Prescription She Never Asked Questions About
- What Is High-Functioning Anxiety?
- What Medication Does — and What It Doesn’t
- How the Medication Question Shows Up in Driven Women
- When Medication Is the Right First Move
- Both/And: Medication Can Be Right and Therapy Is Still Required
- The Systemic Lens: Why Driven Women Get Prescriptions Instead of Therapy
- How to Decide — and How to Begin
- Frequently Asked Questions
The Prescription She Never Asked Questions About
Rina is a hospitalist at Stanford. She’s 39, she’s excellent at her work, and she’s been taking sertraline for three years. She’s never told her department chief. She’s never told most of her colleagues. The prescription came after a fifteen-minute appointment with a GP she saw once; she filled it that afternoon and has been refilling it since.
The anxiety decreased, modestly. Her attachment patterns in her marriage didn’t change. Her overwork didn’t change. The internal critic that runs beneath every shift, every rounding, every conversation with a patient’s family — that didn’t change either. And now, three years in, the medication seems to be doing less. She Googled “sertraline stopped working,” found nine different articles about dosage adjustment, and eventually ended up on my website instead.
What she needed wasn’t a dosage adjustment. What she needed was to understand that the anxiety she’s been managing pharmaceutically has a story — a nervous system signature, an attachment origin, a developmental history — and that medication alone was never going to get to that level.
This post is for Rina. It’s for the driven, ambitious woman with a prescription she’s ambivalent about, or a prescription she’s considering and doesn’t have a framework for evaluating, or a prescription that’s working well and a suspicion that something else might also be needed. My position isn’t anti-medication. It’s precision: the right treatment, at the right time, in the right sequence, for the right reasons.
What Is High-Functioning Anxiety?
High-functioning anxiety isn’t a formal DSM-5 diagnosis. It’s a clinical pattern — one that driven women inhabit at high rates and that is dramatically undertreated as a result of the very functioning that names it.
A clinical pattern characterized by chronic sympathetic arousal, pervasive worry, hypervigilance, and baseline physiological tension — reliably masked by exceptional performance in professional and personal domains. Individuals with high-functioning anxiety often appear to others as composed, capable, and successful, while internally managing significant distress. As David Barlow, PhD, founder of the Center for Anxiety and Related Disorders at Boston University and one of the foremost researchers on anxiety disorders, distinguishes: adaptive anxiety motivates and enhances performance in bounded situations; disordered anxiety is persistent, disproportionate, and impairs well-being even when it doesn’t impair surface-level functioning.
In plain terms: You’re highly functional. You’re also exhausted, chronically vigilant, and waiting for the thing you can’t name to go wrong. The functioning doesn’t mean the anxiety isn’t real. It means no one has offered you help for it, because from the outside you look like you’re doing great.
The definitional tension in high-functioning anxiety is clinical: because driven women perform and achieve, their anxiety is systematically undertreated. Their functioning gets read as the absence of a problem. “But you’re so successful” is one of the loneliest things a driven woman can hear when she’s trying to tell someone she’s not okay.
The internal experience is typically this: a baseline hum of worry that never fully quiets; hypervigilance to potential failure, disappointment, or disapproval; physical tension that she’s learned to normalize (the shoulders, the jaw, the digestive system, the sleep that never fully restores); and an insistence on doing more, planning more, controlling more — not because she loves the doing but because stopping feels dangerous in a way she can’t quite explain.
In my work with clients, I see high-functioning anxiety across a specific cluster of presentations: the physician who reviews her charts three times before signing because she can’t tolerate uncertainty; the tech executive whose first thought upon waking is the worst possible thing that could happen today; the attorney who has never once felt prepared enough, no matter how prepared she is. These women aren’t failing. They’re also not okay.
What Medication Does — and What It Doesn’t
Let’s be precise about the neurobiological mechanism, because precision here matters enormously for making good decisions.
SSRIs — selective serotonin reuptake inhibitors, the category that includes sertraline, escitalopram, and fluoxetine — work at the neurobiological level by increasing serotonin availability in the synaptic cleft. Over time, this process gradually downregulates amygdala reactivity. The amygdala is the brain’s threat detection center — the structure that initiates the fear response, scans for danger, and keeps the nervous system alert. When the amygdala is chronically over-reactive, the result is the baseline hypervigilance and anxious anticipation that characterizes high-functioning anxiety. SSRIs can reduce this reactivity — meaningfully, in many people.
What SSRIs don’t do is update the meaning-making systems that drive the over-reactive response in the first place. They can lower the alarm’s volume. They can’t change what the alarm is responding to. They can’t explain why a specific relational cue causes a disproportionate threat response. They can’t process a stored memory that’s been driving hypervigilance for twenty years. They can’t build the cortical regulatory capacity — the top-down control from the prefrontal cortex — that allows for genuinely flexible responses to threat.
Stephen Porges, PhD, neuroscientist and developer of the Polyvagal Theory, provides the conceptual framework for understanding why this matters. Porges identifies the autonomic nervous system as the foundation of psychological experience — the body’s continuous, unconscious assessment of safety and threat in the environment.
A chronic imbalance in the body’s autonomic nervous system — the network that governs the fight/flight/freeze response, heart rate, digestion, and social engagement capacity — resulting in a persistent state of threat activation. As described by Stephen Porges, PhD, neuroscientist at Indiana University and developer of the Polyvagal Theory, dysregulation occurs when the nervous system remains mobilized for threat even in the absence of actual danger, creating the physiological substrate of chronic anxiety, hypervigilance, and the shutdown states that follow.
In plain terms: The body’s internal alarm system is stuck on. You didn’t choose this. It’s not a character flaw or insufficient willpower. It’s a nervous system that learned — for very good reasons, at some point in your history — that the world requires constant vigilance, and hasn’t yet received the information that you’re safe now.
Benzodiazepines — lorazepam, alprazolam, clonazepam — operate through a different mechanism: acute GABAergic dampening, which provides rapid calming by enhancing the inhibitory neurotransmitter system. They’re effective for acute panic. They’re genuinely inappropriate as a primary treatment for trauma-origin anxiety in driven women, because their mechanism doesn’t address the underlying dysregulation, their withdrawal can intensify anxiety significantly, and their long-term use creates a new layer of physiological complexity that often makes the underlying problem harder to access.
What trauma-informed therapy does that medication cannot: it updates the meaning-making system. It processes stored traumatic material so that the nervous system receives new information. It builds cortical regulatory capacity — the ability to recognize a threat response as a response rather than a fact, and to choose a different action than the one the alarm is prescribing. EMDR, Somatic Experiencing, and Internal Family Systems are the modalities with the strongest evidence for trauma-origin anxiety. Each works differently, but each addresses the source rather than the symptom.
How the Medication Question Shows Up in Driven Women
The choice between medication and therapy — or the question of how to sequence them — looks different for driven women than for the general population, for reasons that are specific and worth understanding.
The first dynamic is the efficiency preference. Medication is faster. It doesn’t require a weekly appointment. It doesn’t require disclosing anything to anyone (most of the time). It allows the internal narrative of “I’m managing it” to remain intact, because the medication is managing it. For driven women who can’t afford — or don’t think they can afford — the vulnerability of a weekly therapy appointment where someone gets close enough to see the actual interior, medication feels like the rational choice.
The cost of this preference is what Rina ran into three years later: modest symptom reduction, unchanged attachment patterns, unchanged overwork, unchanged relationship between self-worth and performance, and a medication that eventually stops being sufficient because it was never treating the right level of the problem.
Ana, 47, is a VC partner who tried three different SSRIs over five years. Each provided partial relief. Each eventually plateaued. She finally started EMDR — and in the processing of a single childhood memory, watched an anxiety pattern she’d been managing pharmaceutically for a decade dissolve. “The medications were doing what they could,” she told me. “They were making the noise manageable. But the thing generating the noise was still there.”
That’s the distinction. Medication manages the noise. Therapy finds and addresses what’s generating it.
Bessel van der Kolk, MD, psychiatrist and trauma researcher and author of The Body Keeps the Score, makes this point with precision: trauma leaves a physiological imprint, not just a psychological memory. Medication can help manage the physiological manifestations of that imprint — the panic, the hypervigilance, the intrusive activation. It doesn’t, by itself, process the imprint. Without that processing, the underlying vulnerability remains, and tends to reassert itself whenever life’s conditions create sufficient load.
The second dynamic is the professional disclosure concern. Rina took her sertraline in private for three years because of legitimate fears about licensure and professional reputation. Physicians face this acutely: mental health disclosures can create complications in licensing processes in several states. Attorneys face it around Bar fitness-for-duty questions. Executives face it around perceived competence. These fears are real, and they shape treatment-seeking in significant ways — often toward more discreet options (medication) and away from the more clinically appropriate ones (therapy with a licensed clinician).
Private self-pay therapy addresses this directly: no insurance records, no EAP, protected by therapist-client privilege. My practice is specifically structured for exactly this kind of confidentiality.
When Medication Is the Right First Move
My clinical position is explicitly not anti-medication. There are presentations where starting with medication is not just appropriate but clinically necessary — and I want to be clear about what those are.
When anxiety is so severe that it’s preventing engagement with therapy — when panic is flooding every session, when depression has created such cognitive and motivational impairment that the client can’t access the emotional and cognitive processing that therapy requires — medication can provide a necessary stabilization floor. It lowers the activation ceiling enough to make therapeutic work possible. This is the legitimate role of medication as a bridge: not the destination, but the access ramp.
When comorbid major depression has significant biological weight — severe vegetative symptoms, significant anhedonia, disrupted sleep and appetite, possible suicidal ideation — medication is often essential to address the acute depressive episode before deeper trauma work is clinically appropriate. You can’t do trauma processing work from a flooded or collapsed nervous system.
And when a client has been in long-term avoidance — years of managing anxiety through control, overwork, and relentless productivity — her nervous system may be chronically dysregulated in ways that make therapy feel initially overwhelming. A carefully monitored trial of medication, in these cases, can lower the activation floor enough that she can begin to tolerate the therapeutic contact that the work requires.
The Polyvagal concept of the “window of tolerance” — the zone of arousal in which a person can think, feel, and function flexibly — is useful here. Medication can help widen that window in specific presentations. Within that wider window, therapy can do the processing work that leads to lasting change. These aren’t competing interventions. They’re potentially sequential and complementary ones.
What I want to push back on is the pattern Rina represents: medication as the default, first, and only intervention for driven women with anxiety — delivered in fifteen minutes without clinical assessment, without conversation about alternatives, without a plan for what happens if the medication is insufficient. That’s not precision medicine. That’s triage medicine applied where something more thoughtful was called for.
Both/And: Medication Can Be Right and Therapy Is Still Required
The explicit Both/And I want to name: medication can be clinically appropriate and insufficient. These are not contradictory. For driven women with high-functioning anxiety that has deep developmental roots, attachment origins, or a trauma history, medication is often genuinely helpful and genuinely not enough.
Medication treats the symptom load. It can reduce anxiety intensity, improve mood, lower the physiological activation that makes daily functioning costly. For someone managing a demanding professional role while simultaneously managing chronic anxiety that hasn’t been treated, this reduction can be significant and real. It creates breathing room.
Therapy treats the source. It explores where the anxiety originated — in early attachment experiences, developmental patterns, specific traumatic events, or the cumulative weight of growing up in an environment that was emotionally unsafe in particular ways. It processes stored material so the nervous system gets new information. It builds the internal resources — cortical regulation, affect tolerance, relational security — that medication can’t build. These are genuinely different interventions operating at different levels of the system.
Ana’s EMDR experience illustrated this with unusual clarity. Five years of SSRIs provided partial, plateau-prone relief. One piece of deep therapeutic work dissolved a decade-old pattern. The SSRIs weren’t wrong. They were addressing the right level of the system that they’re capable of addressing. The EMDR addressed the level they couldn’t.
For many driven women, the most effective treatment model is concurrent: medication to support stability and lower the activation floor while therapy addresses the source. The two don’t interfere with each other. They operate at different registers of the same system. What they require is coordination between prescriber and therapist — and a client who understands what each is doing and why, so that she can give accurate feedback about what’s working and what isn’t.
If you’re currently on medication and feel like you’re managing rather than healing, that’s important clinical information. It might mean the dose needs adjustment. It might mean a different medication is worth trying. It might mean that what you’re managing with medication is the symptom of something that therapy needs to address. A consultation can help you figure out which.
The Systemic Lens: Why Driven Women Get Prescriptions Instead of Therapy
The pattern Rina represents — fifteen minutes, a prescription, no further conversation — isn’t a failure of individual clinicians. It’s a systemic failure with structural causes worth naming.
The fifteen-minute psychiatry appointment model is the primary mechanism. In an encounter of fifteen minutes, there’s no time for a thorough assessment of anxiety’s origins, no time for genuine differential diagnosis, no time for a conversation about the evidence base for psychotherapy, and no realistic alternative to prescribing. The economic pressures and structural realities of mental health care in the United States have produced a system where the most common clinical intervention for anxiety is one that addresses symptom load without addressing source — not because it’s the best intervention, but because it’s the most deliverable one in the available time.
Insurance reimbursement compounds this. Medication management is typically reimbursed at higher rates and with more predictability than weekly psychotherapy. The financial structure of the system creates incentives — for both patients and providers — toward pharmaceutical solutions. This isn’t conspiracy. It’s the predictable outcome of reimbursement structures that weren’t designed with trauma-informed care in mind.
For driven women specifically, the professional disclosure concerns described above — licensure, Bar fitness, executive competence narratives — add an additional structural barrier to therapy-seeking. These concerns are legitimate and they’re underaddressed by a mental health system that hasn’t built adequate confidentiality protections for professionals in high-stakes licensed occupations.
There’s also a gender dimension worth naming directly. Research consistently documents that women are prescribed psychotropic medications at higher rates than men for equivalent symptom presentations. This disparity reflects both systemic healthcare bias and the specific ways women’s distress tends to be clinically received: as something to be managed and quieted rather than understood and treated. The prescription is often the path of least resistance for a system that finds it easier to medicate anxiety than to ask what the anxiety is about.
The scarcity of trauma-informed therapy at scale is the final structural piece. When specialized therapeutic resources are limited, when waitlists are long, when therapists who genuinely understand high-functioning anxiety in professional women are rare — medication fills the gap by default. Not because it’s optimal, but because it’s available. This is a systemic failure that individual women can’t solve, but that they deserve to understand so they can seek out the clinical care that actually addresses their level of need.
If you’re trying to find a therapist who specifically understands anxiety in driven women — who won’t pathologize your ambition or tell you to “slow down” as though that’s the answer — my practice is built for exactly this, and you can connect with me directly to explore whether it’s a fit.
How to Decide — and How to Begin
Here’s the practical clinical decision framework I’d offer any driven woman sitting with the medication-versus-therapy question.
The severity threshold question. How debilitating is the anxiety right now? If it’s significantly impairing daily function — if you can’t sleep, can’t maintain relationships, can’t work at a level that meets your own standards, or are experiencing suicidal ideation — medication is often the appropriate first step. Stabilization before processing. Getting regulated enough to engage with the therapy that addresses the source.
The attachment and developmental history question. Does your anxiety have identifiable roots in early relational experiences — in a parent who was unpredictable, critical, emotionally absent, or difficult to please? In growing up in an environment where emotional safety was contingent on performance? If yes, therapy is going to be essential for any lasting change, because medication cannot rewrite an attachment history. It can manage its current manifestations. Therapy can address the history itself.
The therapy history question. Have you been in therapy before? If so, what did it address? If previous therapy focused primarily on coping skills and symptom management rather than on the developmental origins of your anxiety, there may be a significant layer of work you haven’t yet done — and trauma-informed modalities like EMDR, Somatic Experiencing, or IFS may offer something qualitatively different from what you’ve already tried.
The “what am I managing and what am I treating” question. If you’re currently on medication, it’s worth asking yourself honestly: Am I treating the anxiety, or am I managing it well enough to continue not treating it? There’s nothing inherently wrong with management — sometimes management is all the current life conditions allow for. But if the management has become a permanent substitute for treatment, it’s worth naming that and making a more deliberate choice.
“I stand in the ring / in the dead city / and tie on the red shoes.”
ANNE SEXTON, “The Red Shoes,” The Death Notebooks
For anxiety with clear trauma roots, the therapies with the strongest evidence base are: EMDR (Eye Movement Desensitization and Reprocessing), which processes traumatic memories and updates the nervous system’s threat response; Somatic Experiencing (SE), which releases stored trauma from the body and restores nervous system regulation; and Internal Family Systems (IFS), which works with different parts of the self to heal wounded internal parts and build genuine self-leadership. These modalities address the level of the system that medication doesn’t reach.
You don’t have to choose between medication and therapy. For many women, the most clinically sound path is sequential — therapy informed by medication support — or concurrent, with each intervention addressing a different register of the system. What matters is that the choice is deliberate, informed, and connected to an actual understanding of what each intervention does and doesn’t do.
You deserve that level of clarity about your own care. And if you’re not getting it from your current providers, the quiz on my site is a starting place, or you can reach out directly for an initial conversation about what would actually help. My Fixing the Foundations course also addresses the relational and developmental roots of anxiety for women who want to begin the work before committing to one-on-one therapy.
Q: Can I take medication and do therapy at the same time?
A: Yes — and for many driven women with high-functioning anxiety, concurrent medication and therapy is the most clinically effective approach. Medication lowers the activation floor; therapy addresses the source. These aren’t redundant. They’re complementary interventions operating at different levels. What they require is coordination: your prescriber and therapist should be aware of each other’s work and aligned on the overall treatment approach.
Q: Will SSRIs change my personality or blunt my edge at work?
A: SSRIs modulate neurotransmitter availability; they don’t change core personality. Some people report emotional blunting, particularly at higher doses — this is real and worth monitoring, and if it’s happening, it’s worth discussing dosage adjustment with your prescriber. For most people, appropriately dosed SSRIs reduce the anxiety noise without reducing the drive, creativity, or precision that characterize excellent professional performance.
Q: How do I know if my anxiety is “clinical enough” to need treatment?
A: If your anxiety causes you distress — if it affects your relationships, your quality of life, your ability to rest, or your internal experience even when it doesn’t visibly affect your performance — it’s worth getting assessed. The threshold for “clinical enough” is your subjective suffering, not other people’s ability to observe it. High-functioning anxiety is systematically undertreated precisely because the functioning hides the clinical need.
Q: Will I be on medication forever if I start?
A: Not necessarily. Medication can be used as a stabilization bridge while therapy addresses the source — and once the therapeutic work has built sufficient internal regulatory capacity, many women are able to taper off medication in collaboration with their prescriber. The goal, when possible, is to do enough internal work that the external support becomes less necessary. But this is a clinical decision made case by case, not a rule.
Q: My anxiety is high-functioning — do I really need to treat it?
A: This is a question I hear often, and the honest clinical answer is: the functioning doesn’t reduce the internal cost. Women with high-functioning anxiety often pay for the performance with exhaustion, relationship strain, physical symptoms, and a private experience of their inner lives that is far less comfortable than their outer lives suggest. Treating it isn’t about changing who you are. It’s about reducing the cost of being who you are.
Q: Is there research showing therapy works as well as medication for anxiety?
A: Yes — extensive research supports the efficacy of psychotherapy, particularly trauma-informed modalities, for anxiety disorders. In many studies, therapy produces outcomes equivalent to or better than medication, with more durable effects (lower relapse rates after treatment ends) and no physiological side effects or withdrawal complications. For anxiety with identifiable trauma roots, trauma-informed therapy has a particularly strong evidence base.
Q: How do I find a therapist who won’t just tell me to do breathwork?
A: Look for therapists who are explicitly trauma-informed and who specialize in the clinical population you’re part of. Ask during an initial consultation: What’s your approach to anxiety with a developmental or relational origin? What modalities do you use? Do you understand the specific landscape of high-functioning anxiety in professional women? A therapist with genuine training and specificity will welcome those questions. One who responds with “coping skills” probably isn’t the right fit.
Related Reading
Barlow, David H. Anxiety and Its Disorders: The Nature and Treatment of Anxiety and Panic. 2nd ed. New York: Guilford Press, 2002.
Shapiro, Francine. Getting Past Your Past: Take Control of Your Life with Self-Help Techniques from EMDR Therapy. New York: Rodale, 2012.
WAYS TO WORK WITH ANNIE
Individual Therapy
Trauma-informed therapy for driven women healing relational trauma. Licensed in 10 states.
Executive Coaching
Trauma-informed coaching for ambitious women navigating leadership and burnout.
Fixing the Foundations
Annie’s signature course for relational trauma recovery. Work at your own pace.
Strong & Stable
The Sunday conversation you wished you’d had years earlier. 20,000+ subscribers.
Annie Wright, LMFT
LMFT · Relational Trauma Specialist · W.W. Norton Author
Helping ambitious women finally feel as good as their résumé looks.
Annie Wright is a licensed psychotherapist (LMFT #95719) and trauma-informed executive coach with over 15,000 clinical hours. She works with driven, ambitious women — including Silicon Valley leaders, physicians, and entrepreneurs — in repairing the psychological foundations beneath their impressive lives. Annie is the founder and former CEO of Evergreen Counseling, a multimillion-dollar trauma-informed therapy center she built, scaled, and successfully exited. A regular contributor to Psychology Today, her expert commentary has appeared in Forbes, Business Insider, Inc., NBC, and The Information. She is currently writing her first book with W.W. Norton.
